JP6702866B2 - 合成膜−レシーバー複合体 - Google Patents

合成膜−レシーバー複合体 Download PDF

Info

Publication number
JP6702866B2
JP6702866B2 JP2016533105A JP2016533105A JP6702866B2 JP 6702866 B2 JP6702866 B2 JP 6702866B2 JP 2016533105 A JP2016533105 A JP 2016533105A JP 2016533105 A JP2016533105 A JP 2016533105A JP 6702866 B2 JP6702866 B2 JP 6702866B2
Authority
JP
Japan
Prior art keywords
receiver
polypeptide
complex
cells
target
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016533105A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017504568A5 (enExample
JP2017504568A (ja
Inventor
アバク カーベジアン，
アバク カーベジアン，
ジョルディ マタ−フィンク，
ジョルディ マタ−フィンク，
ジョン ラウンド，
ジョン ラウンド，
デイビッド エー． ベリー，
デイビッド エー． ベリー，
ノーバー ビー． アフェヤン，
ノーバー ビー． アフェヤン，
Original Assignee
ルビウス セラピューティクス， インコーポレイテッド
ルビウス セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52293163&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6702866(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ルビウス セラピューティクス， インコーポレイテッド, ルビウス セラピューティクス， インコーポレイテッド filed Critical ルビウス セラピューティクス， インコーポレイテッド
Publication of JP2017504568A publication Critical patent/JP2017504568A/ja
Publication of JP2017504568A5 publication Critical patent/JP2017504568A5/ja
Application granted granted Critical
Publication of JP6702866B2 publication Critical patent/JP6702866B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0641—Erythrocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/02—Pentosyltransferases (2.4.2)
    • C12Y204/02004—Thymidine phosphorylase (2.4.2.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y403/00—Carbon-nitrogen lyases (4.3)
    • C12Y403/01—Ammonia-lyases (4.3.1)
    • C12Y403/01024—Phenylalanine ammonia-lyase (4.3.1.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Botany (AREA)
  • Developmental Biology & Embryology (AREA)
  • Heart & Thoracic Surgery (AREA)
JP2016533105A 2013-11-18 2014-11-12 合成膜−レシーバー複合体 Expired - Fee Related JP6702866B2 (ja)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US201361962867P 2013-11-18 2013-11-18
US61/962,867 2013-11-18
US201361919432P 2013-12-20 2013-12-20
US61/919,432 2013-12-20
US201461973764P 2014-04-01 2014-04-01
US61/973,764 2014-04-01
US201461991319P 2014-05-09 2014-05-09
US61/991,319 2014-05-09
US201462006825P 2014-06-02 2014-06-02
US201462006832P 2014-06-02 2014-06-02
US201462006829P 2014-06-02 2014-06-02
US62/006,829 2014-06-02
US62/006,825 2014-06-02
US62/006,832 2014-06-02
US201462025367P 2014-07-16 2014-07-16
US62/025,367 2014-07-16
US201462059100P 2014-10-02 2014-10-02
US62/059,100 2014-10-02
PCT/US2014/065304 WO2015073587A2 (en) 2013-11-18 2014-11-12 Synthetic membrane-receiver complexes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019087057A Division JP7116705B2 (ja) 2013-11-18 2019-04-30 合成膜－レシーバー複合体

Publications (3)

Publication Number Publication Date
JP2017504568A JP2017504568A (ja) 2017-02-09
JP2017504568A5 JP2017504568A5 (enExample) 2018-05-31
JP6702866B2 true JP6702866B2 (ja) 2020-06-03

Family

ID=52293163

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016533105A Expired - Fee Related JP6702866B2 (ja) 2013-11-18 2014-11-12 合成膜−レシーバー複合体
JP2019087057A Active JP7116705B2 (ja) 2013-11-18 2019-04-30 合成膜－レシーバー複合体
JP2021095131A Pending JP2021130721A (ja) 2013-11-18 2021-06-07 合成膜−レシーバー複合体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019087057A Active JP7116705B2 (ja) 2013-11-18 2019-04-30 合成膜－レシーバー複合体
JP2021095131A Pending JP2021130721A (ja) 2013-11-18 2021-06-07 合成膜−レシーバー複合体

Country Status (8)

Country Link
US (20) US20150182588A1 (enExample)
EP (1) EP3071515A2 (enExample)
JP (3) JP6702866B2 (enExample)
AU (2) AU2014348683B2 (enExample)
BR (1) BR112016011195A2 (enExample)
CA (1) CA2930665A1 (enExample)
IL (2) IL245671B (enExample)
WO (1) WO2015073587A2 (enExample)

Families Citing this family (157)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10322949B2 (en) 2012-03-15 2019-06-18 Flodesign Sonics, Inc. Transducer and reflector configurations for an acoustophoretic device
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9752113B2 (en) 2012-03-15 2017-09-05 Flodesign Sonics, Inc. Acoustic perfusion devices
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US10689609B2 (en) 2012-03-15 2020-06-23 Flodesign Sonics, Inc. Acoustic bioreactor processes
US9745548B2 (en) 2012-03-15 2017-08-29 Flodesign Sonics, Inc. Acoustic perfusion devices
US10737953B2 (en) 2012-04-20 2020-08-11 Flodesign Sonics, Inc. Acoustophoretic method for use in bioreactors
US9745569B2 (en) 2013-09-13 2017-08-29 Flodesign Sonics, Inc. System for generating high concentration factors for low cell density suspensions
JP6702866B2 (ja) 2013-11-18 2020-06-03 ルビウス セラピューティクス， インコーポレイテッド 合成膜−レシーバー複合体
CA2935960C (en) 2014-01-08 2023-01-10 Bart Lipkens Acoustophoresis device with dual acoustophoretic chamber
WO2015153102A1 (en) 2014-04-01 2015-10-08 Rubius Therapeutics, Inc. Methods and compositions for immunomodulation
US9744483B2 (en) 2014-07-02 2017-08-29 Flodesign Sonics, Inc. Large scale acoustic separation device
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
CN108135940B (zh) 2015-10-14 2022-04-15 株式会社美加细胞 纯化血小板的制造方法
EP3368682B1 (en) * 2015-10-30 2019-12-11 H. Hoffnabb-La Roche Ag Methods of measuring factor d activity and potency of factor d inhibitors
EP3374026A4 (en) * 2015-11-12 2019-05-01 Goetzl, Edward, J. THROMBOZYTE BIOMARKERS AND DIAGNOSTIC METHODS FOR VASCULAR DISEASES
WO2017112784A1 (en) * 2015-12-22 2017-06-29 The Trustees Of The University Of Pennsylvania Spycatcher and spytag: universal immune receptors for t cells
US10782306B2 (en) * 2015-12-24 2020-09-22 Koninklijke Philips N.V. Method and a system for determinations of cell suspensions
SG10202007639SA (en) * 2016-01-11 2020-09-29 Rubius Therapeutics Inc Compositions and methods related to multimodal therapeutic cell systems for immune indications
JP7064665B2 (ja) 2016-03-07 2022-05-11 ファーザー フラナガンズ ボーイズ ホーム ドゥーイング ビジネス アズ ボーイズ タウン ナショナル リサーチ ホスピタル 非侵襲的分子対照
EP3426826A4 (en) * 2016-03-09 2019-09-04 Molecular Stethoscope, Inc. METHOD AND SYSTEMS FOR DETECTING TISSUE STATES
WO2017184583A1 (en) * 2016-04-19 2017-10-26 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Anaplerotic agents for treatment of disorders of propionate and long chain fat metabolism
WO2017190056A1 (en) * 2016-04-28 2017-11-02 William Marsh Rice University Conversion of 1-carbon compounds to products
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
WO2017196798A1 (en) * 2016-05-09 2017-11-16 Chang Jae-Hyung Robert Accelerated method for preparing platelet rich plasma
KR20190026819A (ko) * 2016-07-07 2019-03-13 루비우스 테라퓨틱스, 아이엔씨. 외인성 rna를 발현하는 치료용 세포 시스템과 관련된 조성물 및 방법
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
CN110494543A (zh) 2016-10-19 2019-11-22 弗洛设计声能学公司 通过声学的亲和细胞提取
US10425485B2 (en) * 2016-11-21 2019-09-24 Cisco Technology, Inc. Integrating information centric networking (ICN) over low power and lossy networks (LLNs)
US20180153989A1 (en) 2016-12-02 2018-06-07 Rubius Therapeutics, Inc. Compositions and methods related to cell systems for penetrating solid tumors
NZ755628A (en) * 2017-02-13 2023-09-29 Codexis Inc Engineered phenylalanine ammonia lyase polypeptides
AU2018221227A1 (en) 2017-02-17 2019-08-15 Rubius Therapeutics, Inc. Functionalized erythroid cells
CN110300764A (zh) * 2017-02-17 2019-10-01 Ose免疫疗法 抗SIRPg抗体的新用途
EP3654992A1 (en) 2017-07-19 2020-05-27 Rubius Therapeutics, Inc. Compositions and methods related to multimodal therapeutic cell systems for cardiometabolic disease
EP3654991A1 (en) 2017-07-19 2020-05-27 Rubius Therapeutics, Inc. Compositions and methods related to multimodal therapeutic cell systems for infectious disease
JP2020530454A (ja) * 2017-08-07 2020-10-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 安全な細胞治療薬を生成するためのプラットフォーム
US10960071B2 (en) 2017-08-07 2021-03-30 The Regents Of The University Of California Platform for generating safe cell therapeutics
US20210369858A1 (en) * 2017-08-16 2021-12-02 Board Of Regents, The University Of Texas System Use of exosomes for targeted delivery of therapeutic agents
WO2019040516A1 (en) 2017-08-22 2019-02-28 Rubius Therapeutics, Inc. METHODS AND COMPOSITIONS OF LIPID NANOPARTICLES FOR THE PRODUCTION OF MODIFIED ERYTHROID CELLS
WO2019042628A1 (en) 2017-08-31 2019-03-07 Erytech Pharma ARGININE DEIMINASE ENCAPSULATED WITHIN ERYTHROCYTES AND THEIR USE IN THE TREATMENT OF CANCER AND ARGINASE-1 DEFICIENCY
EP3449935A1 (en) 2017-08-31 2019-03-06 Erytech Pharma Arginine deiminase encapsulated inside erythrocytes and their use in treating cancer and arginase-1 deficiency
CN109580990B (zh) * 2017-09-28 2021-08-06 中国医学科学院基础医学研究所 一种采用原子力显微镜检测细胞表面孔洞的方法
US11708559B2 (en) 2017-10-27 2023-07-25 The Children's Hospital Of Philadelphia Engineered red blood cells having rare antigen phenotypes
US20190160102A1 (en) 2017-11-03 2019-05-30 Rubius Therapeutics, Inc. Compositions and methods related to therapeutic cell systems for tumor growth inhibition
KR20220066413A (ko) 2017-12-14 2022-05-24 프로디자인 소닉스, 인크. 음향 트랜스듀서 구동기 및 제어기
RU2763798C1 (ru) 2017-12-23 2022-01-11 Рубиус Терапьютикс, Инк. Искусственные антигенпрезентирующие клетки и способы их применения
WO2019133881A1 (en) 2017-12-29 2019-07-04 Rubius Therapeutics, Inc. Gene editing and targeted transcriptional modulation for enginerering erythroid cells
MX2020007071A (es) 2018-01-05 2020-11-11 Platelet Biogenesis Inc Composiciones y metodos para producir megacariocitos.
US20190330591A1 (en) 2018-01-10 2019-10-31 Rubius Therapeutics, Inc. Amplifiable rnas for therapeutic cell systems
JP7281633B2 (ja) * 2018-01-29 2023-05-26 地方独立行政法人東京都健康長寿医療センター 平均赤血球年齢を決定する方法
EP3755351A4 (en) 2018-02-22 2021-11-24 Entrada Therapeutics, Inc. COMPOSITIONS AND TREATMENT METHODS FOR MITOCHONDRIAL NEUROGASTROINTESTINAL ENCEPHALOPATHY
AU2019232012A1 (en) 2018-03-08 2020-09-24 Rubius Therapeutics, Inc. Therapeutic cell systems and methods for treating cancer and infectious diseases
US20190309271A1 (en) 2018-03-20 2019-10-10 Rubius Therapeutics, Inc. Therapeutic cell systems and methods for treating homocystinuria
US20190309269A1 (en) 2018-03-20 2019-10-10 Rubius Therapeutics, Inc. Therapeutic cell systems and methods for treating hyperuricemia and gout
JP7474702B2 (ja) 2018-03-28 2024-04-25 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム エキソソームから単離されたｄｎａにおけるエピジェネティック変化の同定法
EP3790890A4 (en) 2018-05-09 2022-03-02 Ohio State Innovation Foundation CYCLIC PEPTIDES OF CELL PENETRATION WITH ONE OR MORE HYDROPHOBIC RESIDUES
US11732009B2 (en) * 2018-06-08 2023-08-22 Glympse Bio, Inc. Activity sensor with tunable analyte
US11028425B2 (en) 2018-06-08 2021-06-08 Glympse Bio, Inc. Diagnosis and monitoring of liver disease
WO2020006539A1 (en) 2018-06-29 2020-01-02 Platelet Biogenesis, Inc. Compositions for drug delivery and methods of use thereof
US20230242640A1 (en) * 2018-08-22 2023-08-03 Ose Immunotherapeutics ANTI-SIRPg Compounds
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
WO2020092355A2 (en) * 2018-10-29 2020-05-07 President And Fellows Of Harvard College Nanobody-glycan modifying enzyme fusion proteins and uses thereof
WO2020113090A1 (en) * 2018-11-30 2020-06-04 Cellphire, Inc. Platelets as delivery agents
US11767511B2 (en) 2018-11-30 2023-09-26 Cellphire, Inc. Platelets as delivery agents
WO2020117852A1 (en) 2018-12-03 2020-06-11 Rubius Therapeutics, Inc. Artificial antigen presenting cells including hla-e and hla-g molecules and methods of use
GB2583560A (en) * 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
CN113660944A (zh) * 2018-12-11 2021-11-16 Q32生物公司 用于补体相关疾病的融合蛋白构建体
US11166996B2 (en) 2018-12-12 2021-11-09 Flagship Pioneering Innovations V, Inc. Anellovirus compositions and methods of use
BR112021013934A2 (pt) 2019-01-18 2021-09-21 Flagship Pioneering, Inc. Composições de trem e seus usos
CN113795263A (zh) 2019-02-20 2021-12-14 鲁比厄斯治疗法股份有限公司 包含可负载抗原呈递多肽的工程化红系细胞及使用方法
WO2020191416A2 (en) 2019-02-28 2020-09-24 Georgia Tech Research Corporation Compositions and methods for logic-gated profiling of biologic activity
EP3935162A1 (en) 2019-03-04 2022-01-12 Flagship Pioneering Innovations VI, LLC Circular polyribonucleotides and pharmaceutical compositions thereof
WO2020198403A2 (en) 2019-03-25 2020-10-01 Flagship Pioneering Innovations Vi, Llc Compositions comprising modified circular polyribonucleotides and uses thereof
CN114007627A (zh) 2019-04-26 2022-02-01 鲁比厄斯治疗法股份有限公司 包含去核类红细胞的缓冲组合物
CA3138529C (en) 2019-05-03 2025-10-07 Cellphire Inc Materials and methods for producing blood products
SG11202112506SA (en) 2019-05-10 2021-12-30 Univ California Modified pluripotent cells
US11162079B2 (en) 2019-05-10 2021-11-02 The Regents Of The University Of California Blood type O Rh-hypo-immunogenic pluripotent cells
KR20220016480A (ko) 2019-05-24 2022-02-09 루비우스 테라퓨틱스, 아이엔씨. 탈핵 적혈구를 생성하는 방법
WO2020243560A1 (en) 2019-05-31 2020-12-03 Flagship Pioneering, Inc. Uses of trem compositions to modulate trna pools
WO2020252436A1 (en) 2019-06-14 2020-12-17 Flagship Pioneering Innovations Vi, Llc Circular rnas for cellular therapy
US20220305128A1 (en) 2019-06-19 2022-09-29 Flagship Pioneering Innovations Vi, Llc Compositions comprising circular polyribonucleotides for protein modulation and uses thereof
FI3990005T3 (fi) 2019-06-26 2025-11-28 Travere Therapeutics Switzerland Gmbh Pegyloitu kystationiini-beta-syntaasi entsyymihoitoa varten homokystinurian hoitamiseksi
WO2021034719A1 (en) 2019-08-16 2021-02-25 Cellphire, Inc. Thrombosomes as an antiplatelet agent reversal agent
CN110941181B (zh) * 2019-08-29 2023-01-20 广东工业大学 一种压电陶瓷连接的刚柔耦合运动平台控制方法
JP2022547295A (ja) 2019-09-05 2022-11-11 ヘマネクスト インコーポレイテッド 一酸化炭素を使用した試薬赤血球の貯蔵のための方法
GB201913592D0 (en) * 2019-09-20 2019-11-06 Univ Bristol Product for therapy and methods
US20240091274A1 (en) * 2019-10-15 2024-03-21 The Regents Of The University Of California TRANSPLANTED CELL PROTECTION VIA Fc SEQUESTRATION
MX2022005362A (es) 2019-11-04 2022-09-23 Flagship Pioneering Inc Composiciones de trem para codones con-raros y usos relacionados.
CN114901804A (zh) 2019-11-04 2022-08-12 鲁比厄斯治疗法股份有限公司 使用牛磺酸或亚牛磺酸产生去核红系细胞的方法
EP4055169A1 (en) 2019-11-04 2022-09-14 Flagship Pioneering, Inc. Methods of modifying a nucleic acid sequence
EP4055149A1 (en) 2019-11-04 2022-09-14 Rubius Therapeutics, Inc. Methods of generating enucleated erythroid cells using myo-inositol
GB201918586D0 (en) * 2019-12-17 2020-01-29 Patterson James Engineered platelets for targeted delivery of a therapeutic agent
EP4096682A1 (en) 2020-01-29 2022-12-07 Flagship Pioneering Innovations VI, LLC Compositions for translation and methods of use thereof
US20230104113A1 (en) 2020-01-29 2023-04-06 Flagship Pioneering Innovations Vi, Llc Delivery of compositions comprising circular polyribonucleotides
US20230340451A1 (en) 2020-01-29 2023-10-26 Flagship Pioneering Innovations Vi, Llc Compositions comprising linear polyribonucleotides for protein modulation and uses thereof
CA3170134A1 (en) 2020-02-04 2021-08-12 Cellphire, Inc. Treatment of von willebrand disease
WO2021162731A1 (en) 2020-02-10 2021-08-19 Rubius Therapeutics, Inc. Engineered erythroid cells including hla-g polypeptides and methods of use thereof
WO2021183818A1 (en) * 2020-03-12 2021-09-16 University Of Florida Research Foundation, Incorporated Recombinant oxalate oxidase and uses thereof
WO2021195544A1 (en) * 2020-03-27 2021-09-30 Platelet Biogenesis, Inc. Novel anucleated cells for the treatment of diseases
IL298362A (en) 2020-05-20 2023-01-01 Flagship Pioneering Innovations Vi Llc Coronavirus antigen compositions and their uses
AU2021275213A1 (en) 2020-05-20 2023-02-02 Flagship Pioneering Innovations Vi, Llc Immunogenic compositions and uses thereof
WO2021236952A1 (en) 2020-05-20 2021-11-25 Flagship Pioneering, Inc. Compositions and methods for producing human polyclonal antibodies
AU2021281453A1 (en) 2020-05-29 2022-11-17 Flagship Pioneering Innovations Vi, Llc. Trem compositions and methods relating thereto
CA3180101A1 (en) 2020-05-29 2021-12-02 Flagship Pioneering Innovations Vi, Llc Trem compositions and methods relating thereto
IL299048A (en) 2020-06-14 2023-02-01 Vertex Pharma Variants of complement factor - 1 fusion structures and preparations containing them and their uses
US20230233514A1 (en) 2020-06-23 2023-07-27 Flagship Pioneering, Inc. Antiviral compounds and methods of using the same
WO2022051629A1 (en) 2020-09-03 2022-03-10 Flagship Pioneering Innovations Vi, Llc Immunogenic compositions and uses thereof
CA3194956A1 (en) 2020-09-11 2022-03-17 Glympse Bio, Inc. Ex vivo protease activity detection for disease detection/diagnostic, staging, monitoring and treatment
JP2024501288A (ja) 2020-12-23 2024-01-11 フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー 修飾ｔｒｅｍの組成物及びその使用
TW202241471A (zh) 2021-01-08 2022-11-01 美商盧比亞斯治療公司 提高個體中NKp30陽性淋巴球的方法及其用途
WO2022150578A1 (en) 2021-01-08 2022-07-14 Rubius Therapeutics, Inc. Methods of treating a tumor in a human subject
US20220273724A1 (en) 2021-02-17 2022-09-01 Cellphire Inc. Freeze-dried platelet derivative compositions for treating antiplatelet induced coagulopathy
TW202304482A (zh) 2021-03-14 2023-02-01 美商盧比亞斯治療公司 於個體中增加nkg2d陽性淋巴球之方法及其用途
CA3214085A1 (en) 2021-03-31 2022-10-06 Darby Rye Schmidt Thanotransmission polypeptides and their use in treating cancer
TW202317179A (zh) 2021-06-03 2023-05-01 美商盧比亞斯治療公司 在個體中治療ｈｐｖ１６－陽性或ｈｐｖ１６－相關的癌症之方法
EP4377457A1 (en) 2021-07-26 2024-06-05 Flagship Pioneering Innovations VI, LLC Trem compositions and uses thereof
EP4271818B1 (en) 2021-09-17 2024-07-31 Flagship Pioneering Innovations VI, LLC Compositions and methods for producing circular polyribonucleotides
WO2023044774A1 (en) * 2021-09-24 2023-03-30 Sichuan Clover Biopharmaceuticals, Inc. Tpo mimetic fusion proteins and methods of use submission of sequence listing as ascii text file
TW202322826A (zh) 2021-10-18 2023-06-16 美商旗艦先鋒創新有限責任公司 用於純化多核糖核苷酸之組成物及方法
MX2024006440A (es) 2021-11-24 2024-08-19 Flagship Pioneering Innovations Vi Llc Composiciones inmunogenicas y sus usos.
CA3238370A1 (en) 2021-11-24 2023-06-01 Flagship Pioneering Innovations Vi, Llc Varicella-zoster virus immunogen compositions and their uses
US20250352638A1 (en) 2021-11-24 2025-11-20 Flagship Pioneering Innovations Vi, Llc Coronavirus immunogen compositions and their uses
JP2025500360A (ja) 2021-12-22 2025-01-09 フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー ポリリボヌクレオチドを精製するための組成物及び方法
IL313714A (en) 2021-12-23 2024-08-01 Flagship Pioneering Innovations Vi Llc Cyclic polyribonucleotides encoding antifusogenic polypeptides
WO2023220083A1 (en) 2022-05-09 2023-11-16 Flagship Pioneering Innovations Vi, Llc Trem compositions and methods of use for treating proliferative disorders
EP4522753A2 (en) 2022-05-13 2025-03-19 Flagship Pioneering Innovations VII, LLC Double stranded dna compositions and related methods
EP4650780A2 (en) 2022-05-25 2025-11-19 Flagship Pioneering Innovations VII, LLC Compositions and methods for modulating circulating factors
AU2023275550A1 (en) 2022-05-25 2024-11-21 Flagship Pioneering Innovations Vii, Llc Compositions and methods for modulating cytokines
JP2025519096A (ja) 2022-05-25 2025-06-24 フラッグシップ パイオニアリング イノベーションズ セブン，エルエルシー 遺伝的ドライバーを調節するための組成物及び方法
AU2023276714A1 (en) 2022-05-25 2024-11-21 Flagship Pioneering Innovations Vii, Llc Compositions and methods for modulation of immune responses
CN119947754A (zh) 2022-05-25 2025-05-06 旗舰创业创新第七有限责任公司 用于调节肿瘤抑制因子和癌基因的组合物和方法
EP4544043A1 (en) 2022-06-22 2025-04-30 Flagship Pioneering Innovations VI, LLC Compositions of modified trems and uses thereof
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
AU2023372397A1 (en) 2022-10-31 2025-05-08 Flagship Pioneering Innovations Vi, Llc Compositions and methods for purifying polyribonucleotides
EP4615465A1 (en) 2022-11-08 2025-09-17 Flagship Pioneering Innovations VI, LLC Compositions and methods for producing circular polyribonucleotides
TW202430215A (zh) 2022-12-14 2024-08-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 用於將治療劑遞送至骨之組成物和方法
US20240252520A1 (en) 2023-01-09 2024-08-01 Beth Israel Deaconess Medical Center, Inc. Therapeutic agents and their use for treating chronic wounds
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
WO2024151673A2 (en) 2023-01-09 2024-07-18 President And Fellows Of Harvard College Recombinant nucleic acid molecules and their use in wound healing
IL322201A (en) 2023-02-17 2025-09-01 Flagship Pioneering Innovations Vii Llc DNA structures containing modified uracil
US20240315237A1 (en) * 2023-02-17 2024-09-26 Abbott Diabetes Care Inc. Methods for single cell analysis of glucose internalization
US20240293582A1 (en) 2023-02-17 2024-09-05 Flagship Pioneering Innovations Vii, Llc Dna compositions comprising modified cytosine
WO2024192422A1 (en) 2023-03-15 2024-09-19 Flagship Pioneering Innovations Vi, Llc Immunogenic compositions and uses thereof
KR20250162610A (ko) 2023-03-15 2025-11-18 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 폴리리보뉴클레오티드를 포함하는 조성물 및 이의 용도
AU2024252590A1 (en) 2023-04-12 2025-10-23 Flagship Pioneering Innovations Vi, Llc Trems for use in correction of missense mutations
WO2025006684A1 (en) 2023-06-28 2025-01-02 Flagship Pioneering Innovations Vi, Llc Circular polyribonucleotides encoding antifusogenic polypeptides
WO2025042786A1 (en) 2023-08-18 2025-02-27 Flagship Pioneering Innovations Vi, Llc Compositions comprising circular polyribonucleotides and uses thereof
WO2025076409A1 (en) * 2023-10-06 2025-04-10 Cz Biohub Sf, Llc Generation of antigen-specific t and b cells using engineered commensals
CN117025553B (zh) * 2023-10-09 2023-12-19 深圳市梓健生物科技有限公司 一种在非超低温下保持病毒活力的病毒保存液及其制备方法
WO2025096807A2 (en) 2023-10-31 2025-05-08 Flagship Pioneering Innovations Vii, Llc Novel therapeutic dna forms

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327710A (en) 1980-06-18 1982-05-04 The United States Of America As Represented By The Secretary Of Agriculture Process for encapsulating additives in resealed erythrocytes for disseminating chemicals via the circulatory system
IL86650A0 (en) 1987-06-30 1988-11-30 Biophor Corp Animal derived cells and liposomes,having an antigenic protein incorporated into their membrane
US5258499A (en) 1988-05-16 1993-11-02 Vestar, Inc. Liposome targeting using receptor specific ligands
US4935223A (en) 1988-08-04 1990-06-19 Board Of Regents, The University Of Texas System Labeled cells for use in imaging
US5676954A (en) 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
EP0517986B1 (en) 1991-06-14 1997-09-10 Communaute Economique Europeenne (Cee) Transformed erythrocytes, process for preparing the same, and their use in pharmaceutical compositions
US5830462A (en) 1993-02-12 1998-11-03 President & Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
US5599705A (en) 1993-11-16 1997-02-04 Cameron; Robert B. In vitro method for producing differentiated universally compatible mature human blood cells
US6984379B1 (en) 1994-04-08 2006-01-10 Children's Hospital of LosAngeles Gene therapy by administration of genetically engineered CD34+ cells obtained from cord blood
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
US5648248A (en) 1994-12-30 1997-07-15 Boehringer Ingelheim International Gmbh Methods for producing differentiated cells from immature hematopoietic cells
US6060052A (en) 1995-10-30 2000-05-09 Systemix, Inc. Methods for use of Mpl ligands with primitive human hematopoietic stem cells
TW520297B (en) 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
EP0932390A1 (en) 1996-10-11 1999-08-04 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method
EP0951216A4 (en) 1996-11-21 2001-05-30 New York Blood Ct Inc METHOD FOR CONVERTING THE BLOOD TYPE
EP0882448B1 (en) 1997-05-05 2005-01-12 DIDECO S.r.l. Method of encapsulating biologically active agents within erythrocytes and apparatus therefor
US6361998B1 (en) 1998-06-25 2002-03-26 Hemosol Inc. Efficient culture of stem cells for the production of hemoglobin
US6197526B1 (en) 1999-01-04 2001-03-06 Dyax Corp. Polypeptides for binding human factor VIII and fragments of human factor VIII
US7109170B2 (en) 1999-06-16 2006-09-19 Saint Louis University Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor
US6624289B1 (en) 1999-06-16 2003-09-23 Saint Louis University Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor
AU781618C (en) 1999-07-02 2006-03-16 Genentech Inc. FVIIa antagonists
AT411997B (de) 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
US6495351B2 (en) 2000-02-08 2002-12-17 Gendel Limited Loading system and method for using the same
US20020151004A1 (en) 2000-07-24 2002-10-17 Roger Craig Delivery vehicles and methods for using the same
WO2002074345A2 (en) 2001-03-16 2002-09-26 Johns Hopkins University School Of Medicine Immune modulation by transduced hematopoietic stem cells expressing antigens and antigen-presenting cell regulatory molecules
US20030207247A1 (en) 2001-12-05 2003-11-06 Cerus Corporation Preparation of red blood cells having reduced immunogenicity
US20030133922A1 (en) 2002-01-15 2003-07-17 Kasha John R. Oral tolerance using allogeneic platelets in ITP
WO2004029200A2 (en) 2002-09-26 2004-04-08 Children's Medical Center Corporation Method of enhancing proliferation and/or hematopoietic differentiation of stem cells
EP1581056B1 (en) 2002-12-13 2010-07-21 Genetix Pharmaceuticals Inc. Therapeutic retroviral vectors for gene therapy
DE10335833A1 (de) * 2003-08-05 2005-03-03 Curevac Gmbh Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
EP1753859B1 (en) * 2004-06-04 2014-07-30 Université Pierre et Marie Curie (Paris 6) A method for producing red blood cells
BRPI0510271A (pt) 2004-06-15 2007-10-30 Baxter Int aplicações ex-vivo agentes terapêuticos microparticulados
FR2873925B1 (fr) 2004-08-05 2006-10-13 Erytech Pharma Soc Par Actions Procede et dispositif de lyse-rescellement pour l'incorporation de principe actif notamment asparaginase ou inositol hexaphosphate, dans des erythrocytes
US7343146B2 (en) * 2004-08-13 2008-03-11 Nokia Corporation Single chip LNA and VCO having similar resonant circuit topology and using same calibration signal to compensate for process variations
DE102004054536A1 (de) * 2004-11-06 2006-05-11 Capsulution Nanoscience Ag Multimodal veränderte Zellen als zellulare Darreichungsformen für aktive Substanzen und als diagnostische Zellpartikel
FR2884717B1 (fr) 2005-04-25 2009-07-03 Erytech Pharma Soc Par Actions Erythrocytes renfermant de l'arginine deiminase
JP5925408B2 (ja) 2005-09-23 2016-05-25 タイジェニックス、ソシエダッド、アノニマ、ウニペルソナルＴｉｇｅｎｉｘ Ｓ．Ａ．Ｕ． 免疫調節活性を有する細胞集団、単離方法および使用
FR2891843A1 (fr) 2005-10-06 2007-04-13 Erytech Pharma Soc Par Actions Erythrocytes contenant du 5-fluorouracile
US7462485B2 (en) * 2005-10-07 2008-12-09 Glaser Lawrence F Modified erythrocytes and uses thereof
US20070243137A1 (en) 2006-04-18 2007-10-18 Nanoprobes, Inc. Cell and sub-cell methods for imaging and therapy
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7531341B1 (en) 2006-06-12 2009-05-12 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
FR2919804B1 (fr) 2007-08-08 2010-08-27 Erytech Pharma Composition et vaccin therapeutique anti-tumoral
US7537923B2 (en) 2007-08-17 2009-05-26 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
FR2925339B1 (fr) 2007-12-24 2010-03-05 Erytech Pharma Medicament pour le traitement du cancer du pancreas
CA2715379A1 (en) 2008-02-13 2009-08-20 Erytech Pharma Formulation and method for the prevention and treatment of skeletal manifestation of gaucher's disease
FR2928270B1 (fr) 2008-03-10 2011-01-21 Erytech Pharma Formulation methode pour la prevention ou le traitement des metastases osseuses et autres maladies de l'os
US8231895B2 (en) 2008-05-22 2012-07-31 Universidade De Coimbra Targeted delivery to human diseases and disorders
US8211656B2 (en) 2008-08-13 2012-07-03 The Invention Science Fund I, Llc Biological targeting compositions and methods of using the same
FR2938332B1 (fr) 2008-11-07 2011-11-25 Erytech Pharma Test predictif de la neutralisation de l'activite asparaginase
EP2379064B1 (en) * 2008-12-15 2020-02-26 Pfizer Inc. Long circulating nanoparticles for sustained release of therapeutic agents
FR2944106B1 (fr) 2009-04-03 2012-09-28 Erytech Pharma Methode de dosage de l'inositol hexaphosphate (ihp).
US9834787B2 (en) 2009-04-09 2017-12-05 Sangamo Therapeutics, Inc. Targeted integration into stem cells
US20120066778A1 (en) 2009-05-19 2012-03-15 Christian Kemmer Control of uric acid homeostasis
PL2493487T3 (pl) 2009-10-27 2017-02-28 Erytech Pharma Kompozycja do indukowania swoistej tolerancji immunologicznej
CN102858153A (zh) 2010-03-12 2013-01-02 加利福尼亚大学董事会 纳米粒子稳定化的脂质体的触发活性物释放
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
JP6219832B2 (ja) 2011-10-17 2017-10-25 マサチューセッツ インスティテュート オブ テクノロジー 細胞内送達
CN104271148A (zh) 2012-02-15 2015-01-07 洛桑聚合联合学院 红细胞结合性治疗剂
HK1206201A1 (en) * 2012-03-13 2016-01-08 Anthrogenesis Corporation Modified erythrocyte precursor cells and uses thereof
US20150086521A1 (en) 2012-03-21 2015-03-26 Erytech Pharma Medicament for the Treatment of Acute Myeloid Leukemia (AML)
US8975072B2 (en) 2012-07-20 2015-03-10 Riken Human erythroid progenitor cell line comprising HPV E6/E7 operably linked to an inducible promoter and method for producing human enucleated red blood cells
US20150246085A1 (en) 2012-11-01 2015-09-03 The Sydney Children's Hospital Network (Randwick & Westmead) Genetically-Modified Probiotic for Treatment of Phenylketonuria
US9675678B2 (en) 2013-01-29 2017-06-13 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treatment of homocystinuria
CN103224957B (zh) * 2013-04-16 2017-08-04 福建三一造血技术有限公司 体外诱导生成含L‑ASPase II的红细胞药物的方法
FR3005420B1 (fr) 2013-05-07 2015-09-18 Erytech Pharma Procede de stabilisation de suspensions d'erythrocytes encapsulant un principe actif, suspensions obtenues.
US10260038B2 (en) 2013-05-10 2019-04-16 Whitehead Institute For Biomedical Research Protein modification of living cells using sortase
PL2994117T3 (pl) 2013-05-10 2023-10-16 Erydel S.P.A. Sposób wytwarzania erytrocytów obciążonych jedną lub większą liczbą substancji będących przedmiotem zainteresowania pod względem farmaceutycznym oraz tak otrzymane erytrocyty
EP3693398A1 (en) 2013-05-10 2020-08-12 Whitehead Institute for Biomedical Research In vitro production of red blood cells with sortaggable proteins
EP2813234A1 (en) 2013-06-11 2014-12-17 Erytech Pharma Composition of erythrocytes encapsulating phenylalanine hydroxylase and therapeutic use thereof
JP6702866B2 (ja) 2013-11-18 2020-06-03 ルビウス セラピューティクス， インコーポレイテッド 合成膜−レシーバー複合体
FR3017299B1 (fr) 2014-02-12 2018-05-18 Erytech Pharma Composition pharmaceutique comprenant des erythrocytes encapsulant une enzyme a plp et son cofacteur
WO2015153102A1 (en) 2014-04-01 2015-10-08 Rubius Therapeutics, Inc. Methods and compositions for immunomodulation
WO2016183482A1 (en) 2015-05-13 2016-11-17 Rubius Therapeutics, Inc. Membrane-receiver complex therapeutics
EP3187190A1 (en) 2015-12-31 2017-07-05 Erytech Pharma Method of treating a mammal, including human, against cancer using methionine and asparagine depletion
SG10202007639SA (en) 2016-01-11 2020-09-29 Rubius Therapeutics Inc Compositions and methods related to multimodal therapeutic cell systems for immune indications
KR20190026819A (ko) 2016-07-07 2019-03-13 루비우스 테라퓨틱스, 아이엔씨. 외인성 rna를 발현하는 치료용 세포 시스템과 관련된 조성물 및 방법
US20180153989A1 (en) 2016-12-02 2018-06-07 Rubius Therapeutics, Inc. Compositions and methods related to cell systems for penetrating solid tumors
AU2018221227A1 (en) 2017-02-17 2019-08-15 Rubius Therapeutics, Inc. Functionalized erythroid cells
WO2019040516A1 (en) 2017-08-22 2019-02-28 Rubius Therapeutics, Inc. METHODS AND COMPOSITIONS OF LIPID NANOPARTICLES FOR THE PRODUCTION OF MODIFIED ERYTHROID CELLS
US20190160102A1 (en) 2017-11-03 2019-05-30 Rubius Therapeutics, Inc. Compositions and methods related to therapeutic cell systems for tumor growth inhibition
WO2019133881A1 (en) 2017-12-29 2019-07-04 Rubius Therapeutics, Inc. Gene editing and targeted transcriptional modulation for enginerering erythroid cells

Also Published As

Publication number Publication date
US20190144827A1 (en) 2019-05-16
WO2015073587A3 (en) 2015-08-06
US20180119101A1 (en) 2018-05-03
US20190309261A1 (en) 2019-10-10
US20180216067A1 (en) 2018-08-02
US20170369843A1 (en) 2017-12-28
US20190309262A1 (en) 2019-10-10
BR112016011195A8 (enExample) 2022-11-08
IL245671B (en) 2021-04-29
US20200002674A1 (en) 2020-01-02
US20150182588A1 (en) 2015-07-02
AU2020260424A1 (en) 2020-11-26
US10301593B2 (en) 2019-05-28
US20190264177A1 (en) 2019-08-29
JP7116705B2 (ja) 2022-08-10
US10329531B2 (en) 2019-06-25
IL281666A (en) 2021-05-31
EP3071515A2 (en) 2016-09-28
US10253296B2 (en) 2019-04-09
US10344263B2 (en) 2019-07-09
AU2014348683B2 (en) 2020-11-05
IL245671A0 (en) 2016-06-30
US20180030411A1 (en) 2018-02-01
US20180208897A1 (en) 2018-07-26
US20190316089A1 (en) 2019-10-17
US10557119B2 (en) 2020-02-11
US20190316090A1 (en) 2019-10-17
JP2021130721A (ja) 2021-09-09
US10301594B1 (en) 2019-05-28
CA2930665A1 (en) 2015-05-21
BR112016011195A2 (pt) 2017-09-19
US20180187154A1 (en) 2018-07-05
WO2015073587A2 (en) 2015-05-21
US20160257932A1 (en) 2016-09-08
US20150306212A1 (en) 2015-10-29
JP2017504568A (ja) 2017-02-09
JP2019142950A (ja) 2019-08-29
US20180265847A1 (en) 2018-09-20
US20180187153A1 (en) 2018-07-05
US20190316091A1 (en) 2019-10-17
US20190376034A1 (en) 2019-12-12
US9644180B2 (en) 2017-05-09
AU2014348683A1 (en) 2016-06-09

Similar Documents

Publication Publication Date Title
JP7116705B2 (ja) 合成膜－レシーバー複合体
US20210180015A1 (en) Membrane-Receiver Complex Therapeutics
US11576934B2 (en) Methods and compositions for immunomodulation
HK40020173A (en) Enucleated hematopoietic cells comprising an exogenous antigen
HK1233539B (en) Methods and compositions for immunomodulation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171110

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180411

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181101

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190125

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190328

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190430

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190813

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200213

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200406

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200507

R150 Certificate of patent or registration of utility model

Ref document number: 6702866

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R157 Certificate of patent or utility model (correction)

Free format text: JAPANESE INTERMEDIATE CODE: R157

LAPS Cancellation because of no payment of annual fees